Breakthrough Insights from Danish Researchers on Tailored Therapies

A groundbreaking overview published today in The Pharmacogenomics Journal has spotlighted the transformative potential of pharmacogenetics in managing chronic inflammatory diseases (CID) across Denmark. Led by researchers from the University of Southern Denmark (SDU) and University Hospital Sønderjylland, the study analyzes data from Denmark's national medical registers spanning 2000 to 2024. It reveals how genetic testing could optimize treatments for thousands of patients, reducing risks like severe side effects and treatment failure.

Chronic inflammatory diseases, including inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis, rheumatoid arthritis (RA), and psoriasis, affect millions in Europe. These conditions stem from an overactive immune response causing persistent inflammation in the gut, joints, or skin. Current therapies like biologics and immunosuppressants often yield variable results due to individual genetic differences in drug metabolism and response.

The Danish approach leverages comprehensive population data, showcasing Europe's leadership in precision medicine. This could pave the way for routine genetic screening, enhancing patient outcomes and healthcare efficiency.

Defining Pharmacogenetics: Genes Meet Drug Therapy

Pharmacogenetics, or pharmacogenomics, studies how genetic variations influence an individual's response to medications. The full term is pharmacogenetics (pharmako- meaning drug, genetics referring to genes). It identifies single nucleotide polymorphisms (SNPs)—single-letter changes in DNA—that alter drug processing enzymes, transporters, or targets.

In CID treatment, step-by-step: (1) A patient undergoes genotyping for key variants; (2) Results guide dosing adjustments or drug selection; (3) Therapeutic drug monitoring follows to confirm efficacy; (4) Adverse events are minimized, improving remission rates. For instance, variants in TPMT or NUDT15 genes slow thiopurine metabolism, risking toxicity without dose reduction.

Europe-wide, initiatives like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) provide dosing guidelines, now applicable to Danish contexts.CPIC Guidelines

Europe's CID Landscape: A Growing Public Health Challenge

IBD prevalence in Europe ranges from 0.3% to 0.8%, with Denmark reporting rising incidence. RA affects about 1% of Europeans, while psoriasis impacts 2-3%, with Denmark's lifetime prevalence at 7.9% and one-year at 5%.

• Denmark: ~30,000-40,000 IBD patients, mirroring Nordic trends.
• Europe: Over 3 million IBD cases, straining healthcare with annual costs exceeding €20 billion.
• Comorbidities: 22.5% of IBD patients develop other immune-mediated inflammatory diseases (IMIDs).

Cultural context: Denmark's universal healthcare and detailed registries enable precise epidemiology, informing pan-European strategies.

Unpacking the Danish Study's Methodology and Data

Leveraging The Danish Register of Medical Product Statistics, researchers quantified drug usage for CID therapies from 2000-2024. Key drugs analyzed: azathioprine (immunosuppressant), mesalazine/sulfasalazine (5-ASAs for mild IBD), and biologics infliximab/adalimumab (anti-TNFs for moderate-severe cases).

Genetic variant frequencies were cross-referenced with PharmGKB and CPIC/DPWG guidelines. Cumulative users: ~19,241 on azathioprine (~801/year potentially needing PGx-guided dosing); up to 13,934 on infliximab/adalimumab (~580/year each at immunogenicity risk).

This real-world evidence underscores PGx feasibility in polypharmacy settings.Explore research jobs in pharmacogenomics.

Azathioprine and Thiopurine Variants

Azathioprine, metabolized to active 6-mercaptopurine, risks myelosuppression in TPMT/NUDT15 poor metabolizers (1-14% Europeans). Danish guidelines recommend pre-treatment genotyping, potentially safeguarding 801 patients annually.

5-Aminosalicylates: Nephrotoxicity Risks

Mesalazine/sulfasalazine (HLA-B*58:01 carriers, ~1-12% prevalence) heighten kidney damage risk. Proactive testing prevents rare but severe cases.

Anti-TNF Biologics: Tackling Immunogenicity

Infliximab/adalimumab lose efficacy in 20-50% due to anti-drug antibodies (ADAs). HLA-DQA1*05 carriers (25-30% Caucasians) face higher ADA risk, affecting ~580 Danes/year per drug.

Photo by Oscar Ivan Esquivel Arteaga on Unsplash

Overcoming Immunogenicity: A Core Challenge

Anti-TNF immunogenicity arises when the immune system produces ADAs, neutralizing drugs and causing loss of response. Factors: genetic predisposition (HLA alleles), dosing intervals, concomitant immunomodulators.

Step-by-step management: (1) Genotype for HLA-DQA1*05; (2) Dose intensify or switch agents if positive; (3) Combine with methotrexate (though limited efficacy); (4) Monitor trough levels/ADAs.

European studies confirm: Proactive strategies cut secondary loss by 50%. Denmark's data quantifies the scale, urging implementation.

Personalized Medicine Revolution in Danish Healthcare

Denmark's Personalized Medicine Strategy (2021-2030) integrates PGx via national biobanks like Copenhagen Hospital Biobank-CID. SDU's Vibeke Andersen, a leading IBD pharmacogeneticist, drives this.

Benefits: 20-30% better remission, fewer hospitalizations, cost savings (€1,000-5,000/patient/year). Europe follows: Netherlands' DPWG leads PGx, influencing EMEA approvals.

Stakeholder views: Patients seek tailored therapies; clinicians value decision support; payers eye efficiency. Real-world case: TPMT testing halved azathioprine toxicities in Nordic pilots.

Spotlight on University of Southern Denmark's Role

SDU's Institute of Regional Health Research pioneers CID pharmacogenetics. Prof. Vibeke Andersen's team integrates genetics, epidemiology, and clinical trials, collaborating with Aalborg University and Odense University Hospital.

Timeline: 2017 multidisciplinary collaboration; 2023 IBD PGx review; 2026 national overview. Impacts: Informed Danish guidelines, EU grants. For aspiring researchers, SDU offers PhDs in precision health.Europe higher ed opportunities.

Barriers and Solutions in PGx Adoption

• Cost: Testing €100-300; offset by savings.
• Evidence gaps: Few RCTs for anti-TNF PGx.
• Implementation: Need EHR integration.
• Solutions: Denmark's registers model; EU-funded trials like PREMED-CAP.

Multi-perspective: Regulators push CPIC alignment; ethicists address equity.

Future Outlook: Trials and Innovations

Ongoing: Characterization of Immunogenicity of TNF Inhibitors (NCT04731831). Europe: Multi-omics biomarkers for biologics.

Horizon: AI-driven PGx panels, combination therapies. Actionable: Advocate genotyping in guidelines.

Photo by Brett Jordan on Unsplash

Opportunities for Europe's Next Generation Researchers

Denmark's model inspires careers in pharmacogenomics. Explore research jobs, postdocs, faculty roles at SDU. Rate professors like Andersen; get advice on academic CVs.